{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05280509",
            "orgStudyIdInfo": {
                "id": "TL-895-209"
            },
            "organization": {
                "fullName": "Telios Pharma, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Na\u00efve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib",
            "officialTitle": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Na\u00efve Myelofibrosis (MF) Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-of-tl-combined-with-ruxolitinib-in-jaki-treatment-mf-subjects-and-subjects-with-mf-who-have-a-suboptimal-response-to-ruxolitinib"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-06-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-03-05",
            "studyFirstSubmitQcDate": "2022-03-05",
            "studyFirstPostDateStruct": {
                "date": "2022-03-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-02-16",
            "lastUpdatePostDateStruct": {
                "date": "2023-02-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Telios Pharma, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-na\u00efve or those who have a suboptimal response to ruxolitinib."
        },
        "conditionsModule": {
            "conditions": [
                "Myelofibrosis",
                "Primary Myelofibrosis",
                "Post-PV MF",
                "Post-ET Myelofibrosis"
            ],
            "keywords": [
                "Myelofibrosis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Phase 1b - Dose Escalation Design Phase 2 - Dose Expansion",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 70,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1b - Dose Level 1",
                    "type": "EXPERIMENTAL",
                    "description": "150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.",
                    "interventionNames": [
                        "Drug: TL-895",
                        "Drug: Ruxolitinib"
                    ]
                },
                {
                    "label": "Phase 1b - Dose Level 2",
                    "type": "EXPERIMENTAL",
                    "description": "300 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.",
                    "interventionNames": [
                        "Drug: TL-895",
                        "Drug: Ruxolitinib"
                    ]
                },
                {
                    "label": "Phase 1b - Dose Level 3",
                    "type": "EXPERIMENTAL",
                    "description": "450 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.",
                    "interventionNames": [
                        "Drug: TL-895",
                        "Drug: Ruxolitinib"
                    ]
                },
                {
                    "label": "Phase 2 - Cohort 1 JAKi treatment-na\u00efve MF",
                    "type": "EXPERIMENTAL",
                    "description": "The RP2D of TL-895 as determined in Phase 1b will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.\n\nThe dose of ruxolitinib will be based on the subject's baseline platelet count.",
                    "interventionNames": [
                        "Drug: TL-895",
                        "Drug: Ruxolitinib"
                    ]
                },
                {
                    "label": "Phase 2 - Cohort 2 suboptimal response to Ruxolitinib",
                    "type": "EXPERIMENTAL",
                    "description": "The RP2D of TL-895 as determined in Phase 1b will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.\n\nThe dose schedule will be the stable ruxolitinib dose schedule as the subject is currently taking prior to entry into the study.",
                    "interventionNames": [
                        "Drug: TL-895",
                        "Drug: Ruxolitinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "TL-895",
                    "description": "TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.",
                    "armGroupLabels": [
                        "Phase 1b - Dose Level 1",
                        "Phase 1b - Dose Level 2",
                        "Phase 1b - Dose Level 3",
                        "Phase 2 - Cohort 1 JAKi treatment-na\u00efve MF",
                        "Phase 2 - Cohort 2 suboptimal response to Ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ruxolitinib",
                    "description": "Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.",
                    "armGroupLabels": [
                        "Phase 1b - Dose Level 1",
                        "Phase 1b - Dose Level 2",
                        "Phase 1b - Dose Level 3",
                        "Phase 2 - Cohort 1 JAKi treatment-na\u00efve MF",
                        "Phase 2 - Cohort 2 suboptimal response to Ruxolitinib"
                    ],
                    "otherNames": [
                        "Jakafi",
                        "Jakavi"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase 1b - Recommended Phase 2 dose of TL-895 in combination with ruxolitinib",
                    "description": "Dose-limiting toxicities (DLTs) will be used to establish the maximum-tolerated dose (MTD) of TL-895 in combination with ruxolitinib. The safety review committee (SRC) will determine the RP2D based on safety and efficacy data of the combination of TL-895 and ruxolitinib.",
                    "timeFrame": "28 days"
                },
                {
                    "measure": "Phase 2 - Spleen Volume Reduction (SVR) at Week 24",
                    "description": "The proportion of subjects achieving SVR of \u226535% at Week 24 by magnetic resonance imaging (MRI) or computed tomography (CT) scan.",
                    "timeFrame": "24 Weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Phase 1b - Spleen Volume Reduction (SVR) at Week 24",
                    "description": "The proportion of subjects achieving \u226535% SVR at Week 24 by MRI or CT scan.",
                    "timeFrame": "24 Weeks"
                },
                {
                    "measure": "Phase 1b - TSS reduction at Week 24",
                    "description": "The proportion of subjects achieving \u226550% reduction in TSS at Week 24 by Myelofibrosis Symptom Assessment Form (MFSAF) v4.0.",
                    "timeFrame": "24 Weeks"
                },
                {
                    "measure": "Phase 2 - TSS reduction at Week 24",
                    "description": "The proportion of subjects achieving \u226550% reduction in TSS at Week 24 by MFSAF v4.0.",
                    "timeFrame": "24 Weeks"
                },
                {
                    "measure": "DOR Spleen",
                    "description": "Time from initial SVR of \u2265 35% by MRI/CT until the first occurrence of disease progression or death",
                    "timeFrame": "48 Months"
                },
                {
                    "measure": "Progression Free Survival",
                    "description": "Time from first dose to progression or death from any cause.",
                    "timeFrame": "48 Month"
                },
                {
                    "measure": "Overall Survival",
                    "description": "Time from first dose to death from any cause",
                    "timeFrame": "48 Months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nSubjects with suboptimal response to ruxolitinib:\n\n* Treatment with at a stable dose of ruxolitinib prior to study entry\n* Subjects \u2265 18 years of age and able to provide informed consent.\n* Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by treating physician according to the World Health Organization (WHO) criteria\n* High-risk, intermediate-2 risk, or intermediate-1 risk, defined by Dynamic International Prognostic System (DIPSS)\n* Palpable spleen measuring \u2265 5 cm below the left lower coastal margin (LLCM) or spleen volume of \u2265 450 cm3 by MRI or CT scan assessment\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Adequate hematological, hepatic, \\& renal function.\n\nExclusion Criteria:\n\nTreatment-naive subjects:\n\n* Prior treatment with any JAKi\n\nSubjects with suboptimal response to ruxolitinib:\n\n* Documented disease progression while on ruxolitinib treatment\n\nAll subjects:\n\n* Prior splenectomy or splenic irradiation within 24 weeks prior to first dose of study treatment\n* Prior treatment with a BTK or BMX inhibitor",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "John Mei",
                    "role": "CONTACT",
                    "phone": "650-542-0136",
                    "email": "jmei@teliospharma.com"
                },
                {
                    "name": "Nikki Stuart",
                    "role": "CONTACT",
                    "email": "nzona@teliospharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of Alabama at Birmingham",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35294",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "Gabrail Cancer Center",
                    "status": "RECRUITING",
                    "city": "Canton",
                    "state": "Ohio",
                    "zip": "44718",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.79895,
                        "lon": -81.37845
                    }
                },
                {
                    "facility": "University of Cincinnati (UC)",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45267",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "The University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "CHU Angers",
                    "status": "RECRUITING",
                    "city": "Angers",
                    "zip": "49100",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.46667,
                        "lon": -0.55
                    }
                },
                {
                    "facility": "AP-HM - H\u00f4pital de la Timone",
                    "status": "RECRUITING",
                    "city": "Marseille",
                    "zip": "13005",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.29551,
                        "lon": 5.38958
                    }
                },
                {
                    "facility": "CHU de Nice - Hopital L'Archet II",
                    "status": "RECRUITING",
                    "city": "Nice",
                    "zip": "06200",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.70313,
                        "lon": 7.26608
                    }
                },
                {
                    "facility": "H\u00f4pital Saint Louis - AP-HP",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "zip": "75010",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "Centre Hospitalier Lyon Sud",
                    "status": "RECRUITING",
                    "city": "Pierre-B\u00e9nite",
                    "zip": "69495",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.7009,
                        "lon": 4.82511
                    }
                },
                {
                    "facility": "Marien Hospital Duesseldorf",
                    "status": "RECRUITING",
                    "city": "D\u00fcsseldorf",
                    "zip": "40479",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.22172,
                        "lon": 6.77616
                    }
                },
                {
                    "facility": "Klinik fur Innere Medizin IV - Hamatologie/Onkologie, Universitatsklinikum Hall",
                    "status": "RECRUITING",
                    "city": "Halle",
                    "zip": "40479",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.48159,
                        "lon": 11.97948
                    }
                },
                {
                    "facility": "IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola",
                    "status": "RECRUITING",
                    "city": "Bologna",
                    "zip": "40138",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 44.49381,
                        "lon": 11.33875
                    }
                },
                {
                    "facility": "Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano",
                    "status": "RECRUITING",
                    "city": "Milano",
                    "zip": "20122",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "Azienda Ospedaliera di Perugia-Ospedale S. Maria della Misericordia",
                    "status": "RECRUITING",
                    "city": "Perugia",
                    "zip": "06129",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 43.1122,
                        "lon": 12.38878
                    }
                },
                {
                    "facility": "Pratia Onkologia Katowice",
                    "status": "RECRUITING",
                    "city": "Katowice",
                    "zip": "40-519",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 50.25841,
                        "lon": 19.02754
                    }
                },
                {
                    "facility": "Hospital Universitari Arnau de Vilanova",
                    "status": "RECRUITING",
                    "city": "Lleida",
                    "zip": "25198",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.61674,
                        "lon": 0.62218
                    }
                },
                {
                    "facility": "Hospital Universitario Ramon y Cajal",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28034",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario Virgen de la Victoria",
                    "status": "RECRUITING",
                    "city": "M\u00e1laga",
                    "zip": "29010",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 36.72016,
                        "lon": -4.42034
                    }
                },
                {
                    "facility": "Hospital Quironsalud de Zaragoza",
                    "status": "RECRUITING",
                    "city": "Zaragoza",
                    "zip": "50006",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.65606,
                        "lon": -0.87734
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000055728",
                    "term": "Primary Myelofibrosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009196",
                    "term": "Myeloproliferative Disorders"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M28312",
                    "name": "Primary Myelofibrosis",
                    "asFound": "Myelofibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12149",
                    "name": "Myeloproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4705",
                    "name": "Primary Myelofibrosis",
                    "asFound": "Myelofibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1311",
                    "name": "Chronic Myeloproliferative Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M1474",
                    "name": "Janus Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M2889",
                    "name": "Tyrosine Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T22",
                    "name": "Tyrosine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}